



## AstraZeneca Pharma India Limited

Regd. Office 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

### FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 JUNE 2010

Rs. in lakhs (except for number of shares)

Sl. No.	Particulars	3 Months Ended 30.06.2010 (Unaudited)	3 Months Ended 30.06.2009 (Unaudited)	6 Months Ended 30.06.2010 (Unaudited)	6 Months Ended 30.06.2009 (Unaudited)	Previous Accounting Year Ended 31.12.2009 (Audited)
1	(a) Net sales (net of excise duty)	10,595.60	9,685.79	19,824.01	17,329.75	38,552.12
	(b) Other operating income:					
	- Service income	495.59	338.57	1,057.97	815.64	1,111.21
2	Expenditure					
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	(438.51)	(88.92)	(839.57)	(93.84)	12.76
	(b) Consumption of raw materials and packing materials	1,504.77	935.76	2,834.75	1,754.85	4,575.41
	(c) Purchase of traded goods	2,098.37	2,107.27	4,121.18	3,802.80	7,507.77
	(d) Employees cost	3,032.10	2,117.30	5,712.60	4,244.75	6,282.94
	(e) Depreciation	175.79	151.88	333.40	298.08	607.67
	(f) Other expenditure	3,714.81	2,407.20	7,372.11	4,713.42	10,398.26
	(g) Total	10,087.13	7,632.49	19,534.47	14,719.86	31,364.81
3	Profit from operations before other income, interest & exceptional items (1-2)	1,004.06	2,289.87	1,347.51	3,225.53	8,278.52
4	Other income	106.68	114.30	185.32	388.50	574.40
5	Profit before interest & exceptional items (3+4)	1,110.74	2,404.17	1,512.83	3,614.03	8,852.92
6	Interest	-	-	-	13.70	13.70
7	Profit after interest but before exceptional items (5-6)	1,110.74	2,404.17	1,512.83	3,600.33	8,839.22
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	1,110.74	2,404.17	1,512.83	3,600.33	8,839.22
10	Tax expense	379.29	875.74	519.98	1,344.45	3,077.49
11	Net profit from ordinary activities after tax (9-10)	731.45	1,528.43	992.85	2,255.88	5,761.73
12	Extraordinary item	-	-	-	-	-
13	Net profit for the period (11-12)	731.45	1,528.43	992.85	2,255.88	5,761.73
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year	-	-	-	-	13,851.82
16	Basic and diluted earnings (Rs) per share (not annualised)	2.93	6.11	3.97	9.02	23.05
17	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters' and promoter group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950	22,499,950	22,499,950	22,499,950	22,499,950
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%	89.9998%	89.9998%	89.9998%	89.9998%

#### Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 27 July 2010.
- Status of investor complaints: a) Pending as on 1 April 2010 - NIL b) Received during the quarter - 3 c) Disposed off during the quarter - 3 d) Pending as on 30 June 2010 - NIL.
- The board of directors at their meeting held on 23 February 2010 have approved the change in the company's statutory accounting year from 'January-December' to 'April-March'. Accordingly, the financial accounts and annual report for the year ending 31 March 2011 shall be for a period of 15 months, i.e. from 1 January 2010 to 31 March 2011.
- The Company's sole reportable business segment is - 'Healthcare'. The other segments are not material and are hence disclosed as 'Others'. Others comprise service income pertaining to clinical trials and co-promotion activities.
- Previous period figures have been regrouped / reclassified, wherever necessary to conform to the current period's presentation.

### Segment wise revenue, results and capital employed

(Rs. in lakhs)

Sl. No.	Particulars	3 Months Ended 30.06.2010 (Unaudited)	Corresponding 3 Months Ended in the previous Year 30.06.2009 (Unaudited)	6 Months Ended 30.06.2010 (Unaudited)	Corresponding 6 Months Ended in the previous Year 30.06.2009 (Unaudited)	Previous Accounting Year Ended 31.12.2009 (Audited)
1	Segment Revenue					
	(a) Healthcare	10,600.98	9,593.39	19,834.82	17,342.79	38,583.38
	(b) Others	495.59	338.57	1,057.97	815.64	1,111.21
	Total	11,096.57	9,929.96	20,892.59	17,958.43	39,694.59
	Less: Inter-segment Revenue	-	-	-	-	-
	Net Income From Operations	11,096.57	9,929.96	20,892.59	17,958.43	39,694.59
2	Segment Results					
	Profit before Tax and interest					
	(a) Healthcare	1,008.65	2,292.40	1,349.53	3,229.15	8,286.13
	(b) Others	0.79	5.07	8.59	9.42	23.85
	Total	1,009.44	2,297.47	1,358.12	3,238.57	8,309.78
	Add: Other Income	101.30	106.70	154.71	375.46	543.14
	Less: Interest	-	-	-	13.70	13.70
	Total Profit Before Tax	1,110.74	2,404.17	1,512.83	3,600.33	8,839.22
3	Capital Employed					
	(a) Healthcare	9,400.05	8,789.16	9,400.05	8,789.16	11,595.38
	(b) Others	90.79	(524.15)	90.79	(524.15)	(378.11)
	(c) Unallocated	5,963.49	5,625.84	5,963.49	5,625.84	3,234.55
	Total	15,454.33	13,870.85	15,454.33	13,870.85	14,451.82

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for other segments for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

### Disclosure of Balance Sheet Items as per clause 41 (V) (h) of Listing Agreement

(Rs. in lakhs)

Particulars	For the 6 months ended 30.06.2010 (Unaudited)	For the 6 months ended 30.06.2009 (Unaudited)
<b>SHAREHOLDERS' FUNDS:</b>		
(a) Capital	500.00	500.00
(b) Reserves and Surplus	14,954.33	13,370.85
<b>LOAN FUNDS</b>		
<b>TOTAL</b>	<b>15,454.33</b>	<b>13,870.85</b>
<b>FIXED ASSETS</b>	<b>3,581.54</b>	<b>2,985.25</b>
<b>INVESTMENTS</b>	<b>0.57</b>	<b>0.57</b>
<b>DEFERRED TAX ASSETS</b>	<b>478.96</b>	<b>323.40</b>
<b>CURRENT ASSETS, LOANS AND ADVANCES</b>		
(a) Inventories	4,979.57	3,819.37
(b) Sundry Debtors	4,966.65	5,544.89
(c) Cash and Bank balances	6,187.82	6,506.74
(d) Other current assets	537.10	244.11
(e) Loans and Advances	2,647.42	2,502.24
Less: Current Liabilities and Provisions		
(a) Liabilities	(6,786.08)	(6,436.80)
(b) Provisions	(1,457.02)	(1,629.12)
<b>MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)</b>		
<b>PROFIT AND LOSS ACCOUNT</b>		
<b>TOTAL</b>	<b>15,454.33</b>	<b>13,870.85</b>

By Order of the Board of Directors  
For AstraZeneca Pharma India Limited

Place : Bangalore  
Dated : 27 July 2010

Anandh Balasundaram  
Managing Director